290 related articles for article (PubMed ID: 19739128)
1. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract][Full Text] [Related]
2. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract][Full Text] [Related]
3. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer.
Ellinger J; Kahl P; von der Gathen J; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Bastian PJ; von Ruecker A; Müller SC; Rogenhofer S
Cancer Invest; 2012 Feb; 30(2):92-7. PubMed ID: 22149091
[TBL] [Abstract][Full Text] [Related]
4. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma.
Park YS; Jin MY; Kim YJ; Yook JH; Kim BS; Jang SJ
Ann Surg Oncol; 2008 Jul; 15(7):1968-76. PubMed ID: 18470569
[TBL] [Abstract][Full Text] [Related]
5. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
[TBL] [Abstract][Full Text] [Related]
6. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma.
Mosashvilli D; Kahl P; Mertens C; Holzapfel S; Rogenhofer S; Hauser S; Büttner R; Von Ruecker A; Müller SC; Ellinger J
Cancer Sci; 2010 Dec; 101(12):2664-9. PubMed ID: 20825416
[TBL] [Abstract][Full Text] [Related]
7. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma.
Ellinger J; Kahl P; Mertens C; Rogenhofer S; Hauser S; Hartmann W; Bastian PJ; Büttner R; Müller SC; von Ruecker A
Int J Cancer; 2010 Nov; 127(10):2360-6. PubMed ID: 20162570
[TBL] [Abstract][Full Text] [Related]
9. Histone H3 lysine 4 monomethylation (H3K4me1) and H3 lysine 9 monomethylation (H3K9me1): distribution and their association in regulating gene expression under hyperglycaemic/hyperinsulinemic conditions in 3T3 cells.
Gupta J; Kumar S; Li J; Krishna Murthy Karuturi R; Tikoo K
Biochimie; 2012 Dec; 94(12):2656-64. PubMed ID: 22951486
[TBL] [Abstract][Full Text] [Related]
10. Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients.
Song JS; Kim YS; Kim DK; Park SI; Jang SJ
Pathol Int; 2012 Mar; 62(3):182-90. PubMed ID: 22360506
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA
Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043
[TBL] [Abstract][Full Text] [Related]
13. Global histone modifications predict prognosis of resected non small-cell lung cancer.
Barlési F; Giaccone G; Gallegos-Ruiz MI; Loundou A; Span SW; Lefesvre P; Kruyt FA; Rodriguez JA
J Clin Oncol; 2007 Oct; 25(28):4358-64. PubMed ID: 17906200
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
15. Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma.
Rogenhofer S; Kahl P; Holzapfel S; VON Ruecker A; Mueller SC; Ellinger J
Anticancer Res; 2012 Mar; 32(3):879-86. PubMed ID: 22399607
[TBL] [Abstract][Full Text] [Related]
16. Abnormal histone modification patterns in lupus CD4+ T cells.
Hu N; Qiu X; Luo Y; Yuan J; Li Y; Lei W; Zhang G; Zhou Y; Su Y; Lu Q
J Rheumatol; 2008 May; 35(5):804-10. PubMed ID: 18398941
[TBL] [Abstract][Full Text] [Related]
17. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer.
Schneider AC; Heukamp LC; Rogenhofer S; Fechner G; Bastian PJ; von Ruecker A; Müller SC; Ellinger J
BJU Int; 2011 Oct; 108(8 Pt 2):E290-6. PubMed ID: 21627749
[TBL] [Abstract][Full Text] [Related]
18. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y
J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689
[TBL] [Abstract][Full Text] [Related]
19. Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer.
Ellinger J; Bachmann A; Göke F; Behbahani TE; Baumann C; Heukamp LC; Rogenhofer S; Müller SC
Urol Int; 2014; 93(1):113-8. PubMed ID: 24556868
[TBL] [Abstract][Full Text] [Related]
20. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
Bianco-Miotto T; Chiam K; Buchanan G; Jindal S; Day TK; Thomas M; Pickering MA; O'Loughlin MA; Ryan NK; Raymond WA; Horvath LG; Kench JG; Stricker PD; Marshall VR; Sutherland RL; Henshall SM; Gerald WL; Scher HI; Risbridger GP; Clements JA; Butler LM; Tilley WD; Horsfall DJ; Ricciardelli C;
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2611-22. PubMed ID: 20841388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
